SIG
TSHA icon

Sargent Investment Group’s Taysha Gene Therapies TSHA Stock Holding History

Sargent Investment Group’s Portfolio TSHA Stock Details TSHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-25,634
Closed -$16.9K – 216
2023
Q2 		$16.9K Buy
25,634
+6,065
+31% +$4.39K ﹤0.01% 201
2023
Q1 		$15.1K Sell
19,569
-23,418
-54% -$30.3K ﹤0.01% 197
2022
Q4 		$97.2K Buy
42,987
+17,745
+70% +$35.9K 0.03% 184
2022
Q3 		$47K Buy
25,242
+7,454
+42% +$27.1K 0.01% 182
2022
Q2 		$66K Buy
17,788
+7,132
+67% +$28.3K 0.02% 181
2022
Q1 		$69K Buy
+10,656
New +$79.7K 0.02% 185

Other funds holding TSHA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

Sargent Investment Group's TSHA Position: Q3 2023 in Review

Sargent Investment Group sold out of Taysha Gene Therapies (TSHA) in Q3 2023, closing a stake of 25,634 shares — an estimated $16.9K sold.

Sargent Investment Group first reported a position in TSHA in Q1 2022 and held it in 6 quarters. The position peaked at $97.2K in Q4 2022. 63 funds tracked by Wall St. Rank hold TSHA as of Q3 2023.

  • Sargent Investment Group reported no remaining Taysha Gene Therapies position as of Q3 2023 after selling out during the quarter.
  • Sargent Investment Group sold 25,634 Taysha Gene Therapies shares in Q3 2023, an estimated $16.9K.
  • Sargent Investment Group first reported a position in Taysha Gene Therapies in Q1 2022 and held it in 6 quarters.
  • Sargent Investment Group's Taysha Gene Therapies position peaked at $97.2K in Q4 2022.
  • 63 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q3 2023.

Based on Sargent Investment Group's 13F filing for Q3 2023, filed 13 Nov 2023.